# Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

> **NCT05514002** · PHASE4 · TERMINATED · sponsor: **Fatimah Dawood** · enrollment: 3988 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Fluzone Quadrivalent
- **BIOLOGICAL:** Flublok Quadrivalent

## Key facts

- **NCT ID:** NCT05514002
- **Lead sponsor:** Fatimah Dawood
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-13
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 3988 (ACTUAL)
- **Why stopped:** Insufficient funding.
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514002, "Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05514002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*